51% of COVID-19 patients report they experienced the loss of smell and taste up to five months after infection. On average, once their senses were restored, people reported a loss in sensitivity to smell and taste.
Study reveals those with frontotemporal dementia have greater white matter hyperintensity than those with other forms of dementia. The amount of white matter hyperintensity was associated with the severity of FTD symptoms.
Contrary to popular belief, women with multiple sclerosis may not be at higher risk for complications during pregnancy, such as gestational diabetes or still-birth. However, babies of mothers with MS are more likely to be induced or believed by elective C-sections.
Enlarged perivascular spaces around small blood vessels in the brain may be a biomarker for cognitive decline, and ultimately dementia, a new study reports.
While 40% of people with primary progressive aphasia have underlying Alzheimer's disease, a new study suggests they may not develop the memory problems associated with Alzheimer's.
Researchers identified five unapproved drugs in dangerous combinations and doses in over-the-counter cognitive enhancement drugs. Side effects of the unapproved drugs include increases and decreases in blood pressure, agitation, and sedation.
A genetic variation that alters the metabolism of glutathione may be responsible for cognitive decline in people who do not have other associated biomarkers, a new study reports.
Anticholinergic medications, commonly used for conditions including allergies, high blood pressure, Parkinson's disease, and motion sickness, have been linked to an increased risk of cognitive decline and memory problems, especially in those with genetic risk factors for Alzheimer's disease.
Sleep disturbances may be an outcome of Alzheimer's in those with a genetic predisposition, but not a cause of dementia. Those with genetic risk factors for Alzheimer's tend to have shorter sleep durations and are more likely to be early risers but are less likely to suffer from insomnia.